Stem cell therapy companies take different roads to reproducibility

The takeoff of induced pluripotent stem cell-based therapies has been throttled by reproducibility and scalability limitations — the very features that are the technology’s biggest promise. To break through these barriers, companies are working to automate the manufacturing process, or in some cases, shortcut it. 

The promise of an inexhaustible supply of patient-specific or universally compatible cells capable of treating a wide range of diseases with unprecedented precision and scalability has long been the dream of induced pluripotent stem cell (iPSC) technology...